Massive french study tracks Real-World health of half a million diabetes patients

NCT ID NCT05882071

Summary

This study aims to understand how SGLT2i diabetes drugs are prescribed and used in France by analyzing health records. It will track over 500,000 patients starting this treatment to see if it is linked to real-world health outcomes like heart attacks, strokes, heart failure, and kidney disease. The goal is to gather knowledge about the drug's use and potential effects, not to test a new treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boehringer Ingelheim

    Paris, 75013, France

Conditions

Explore the condition pages connected to this study.